Alzheimer’s

Brain injury
Biotech

Startup Arkuda targets rapidly advancing, rare form of dementia

By Jonathan Saltzman — Boston Globe

Flood gate
First Opinion

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

By Dennis J. Selkoe

Alzheimers Association
In the Lab

New prize offers $2 million for finding key to Alzheimer’s in past research

By Sharon Begley

Empty pipeline
Pharma

That pathetic Alzheimer’s pipeline? It’s even worse than you think

By Sharon Begley

Pharmalot

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

By Ed Silverman

Adam's Take

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

By Adam Feuerstein

Alzheimer's brain illustration - Loss of connection between cells
Pharmalot

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

By Ed Silverman

Glen Campbell
Health

Fans ‘didn’t care if he messed up’: Glen Campbell’s doctor discusses his struggle with Alzheimer’s

By Damian Garde

Bugula neritina
Biotech

In small Alzheimer’s study, hints of modest benefit from unusual drug

By Sharon Begley

Pharmalot

Pharmalot, Pharmalittle: Former compounder told staff to stop ‘fudging’ after meningitis outbreak

By Ed Silverman

Eli Lilly headquarters
Pharmalot

Lilly cuts 200 R&D jobs, but insists an Alzheimer’s failure is not the cause

By Ed Silverman

Play
Signal Podcast

Listen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’

By Luke Timmerman and Meg Tirrell

Pharmalot

Pharmalot, Pharmalittle: Handful of doctors responsible for high levels of fentanyl prescriptions

By Ed Silverman

Senior Citizens Care
Health

Dramatic decline in dementia seen among older adults in the US

By Sharon Begley

Aging and loneliness
Health

Loneliness is bad for your health. This new campaign aims to curb isolation

By Judith Graham

Alzheimer's brain illustration - Loss of connection between cells
In the Lab

Their brains had the telltale signs of Alzheimer’s. So why did they still have nimble minds?

By Sharon Begley

Voting with Alzheimers
Politics

Alzheimer’s is eroding his memory, but not his determination to vote

By Rebecca Robbins

Pharmalot

Pharmalot, Pharmalittle: Valeant sued by Sprout investors over female libido pill

By Ed Silverman

Rebecca genetic testing
Play
Business

Watch: Genetic tests promised to help me achieve peak fitness. What I got was a fiasco

By Rebecca Robbins

Turmeric powder
Gut Check

Can curcumin spice treat Alzheimer’s disease?

By Sharon Begley

In the Lab

MIT’s Susan Lindquist, a pioneer in science, dies at 67

By Bryan Marquard — Boston Globe

Pharmalot

Pharmalot, Pharmalittle: New bill would create review board for drug prices

By Ed Silverman

Amyloid plaque Alzheimers
Business

A big Alzheimer’s drug trial now wrapping up could offer real hope — or crush it

By Damian Garde

Peter Walter - UCSF
In the Lab

Peter Walter just won the Breakthrough Prize. His work? Trying to heal human brains

By Usha Lee McFarling

Pharmalot

Pharmalot, Pharmalittle: FDA fast tracks Biogen drug for Alzheimer’s

By Ed Silverman

Gene Wilder
Health

Gene Wilder died of Alzheimer’s. His family explains why they didn’t disclose his diagnosis

By Dylan Scott

End Notes
Endnotes

How do you honor a dementia patient’s end-of-life-wishes?

By Bob Tedeschi

DNA FOOTBALL
Business

Athletes are keeping their distance from a genetic test for concussion risks

By Rebecca Robbins

Undertreating Alzheimer's
First Opinion

Stop undertreating Alzheimer’s disease

By Gary W. Small

Your daily dose of news in health and medicine

Privacy Policy